Eltrombopag Teva: Uses, Dosage & Side Effects
A thrombopoietin receptor agonist (TPO-RA) that stimulates platelet production for the treatment of chronic immune thrombocytopenia and severe aplastic anemia
Eltrombopag Teva is a prescription oral thrombopoietin receptor agonist (TPO-RA) used to increase platelet counts in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. It is also approved for the treatment of thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection to enable initiation and maintenance of interferon-based antiviral therapy, and as part of combination immunosuppressive therapy for adult patients with severe aplastic anemia (SAA). Eltrombopag works by binding to the transmembrane domain of the thrombopoietin receptor (c-Mpl), stimulating intracellular signaling pathways that promote megakaryocyte proliferation and differentiation, ultimately leading to increased platelet production from the bone marrow.
Quick Facts: Eltrombopag Teva
Key Takeaways
- Eltrombopag Teva is a thrombopoietin receptor agonist used to treat chronic immune thrombocytopenia (ITP) in patients who have not responded adequately to first-line therapies such as corticosteroids, immunoglobulins, or splenectomy.
- The medication must be taken on an empty stomach – at least 2 hours before or 4 hours after dairy products, antacids, or mineral supplements containing calcium, iron, magnesium, aluminum, selenium, or zinc, as these significantly reduce absorption.
- Regular monitoring of liver function (ALT, AST, bilirubin) is mandatory before starting treatment, every 2 weeks during dose titration, and monthly once on a stable dose, as eltrombopag may cause hepatotoxicity.
- Platelet counts should not be normalized – the goal is to achieve and maintain a platelet count sufficient to prevent bleeding (generally ≥50 × 109/L), not to reach normal levels, as excessive platelet counts may increase thrombotic risk.
- Eltrombopag Teva is a generic version of Revolade (Promacta in the US), offering the same active substance, bioequivalence, and therapeutic efficacy at the 25 mg film-coated tablet strength.
What Is Eltrombopag Teva and What Is It Used For?
Eltrombopag Teva contains the active substance eltrombopag, a small-molecule, non-peptide thrombopoietin (TPO) receptor agonist. Thrombopoietin is the primary hormone responsible for regulating platelet production in the body. It is produced mainly by the liver and kidneys and acts on megakaryocytes – the large bone marrow cells from which platelets are derived. In healthy individuals, TPO binds to its receptor (c-Mpl) on the surface of megakaryocyte progenitor cells, triggering intracellular signaling cascades that drive megakaryocyte proliferation, maturation, and ultimately the release of platelets into the bloodstream.
Unlike recombinant TPO or peptide TPO mimetics that bind to the extracellular domain of the c-Mpl receptor, eltrombopag has a unique mechanism of action: it interacts with the transmembrane domain of the TPO receptor. This means that eltrombopag and endogenous TPO can bind to the receptor simultaneously without competing for the same binding site, resulting in additive or synergistic activation of downstream signaling pathways, including the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway, the mitogen-activated protein kinase (MAPK) pathway, and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. The result is enhanced proliferation and differentiation of megakaryocytes, leading to increased platelet production.
Eltrombopag was first approved by the U.S. Food and Drug Administration (FDA) under the brand name Promacta in 2008, and subsequently by the European Medicines Agency (EMA) under the brand name Revolade. Eltrombopag Teva is a generic version that contains the same active substance at the same strength (25 mg film-coated tablets), having demonstrated bioequivalence to the reference product. This means it is absorbed into the body at the same rate and to the same extent as the originator product.
Approved Indications
Eltrombopag Teva is approved for the following clinical indications, each representing a condition characterized by inadequate platelet production or excessive platelet destruction:
- Chronic Immune Thrombocytopenia (ITP): ITP is an autoimmune disorder in which the immune system mistakenly attacks and destroys platelets, leading to low platelet counts and an increased risk of bleeding. Eltrombopag is indicated for adult ITP patients aged 18 years and older who have had an insufficient response to other treatments, including corticosteroids, intravenous immunoglobulin (IVIg), anti-D immunoglobulin, or splenectomy. In pediatric ITP patients aged 1 year and older, eltrombopag is indicated when the condition is chronic (lasting more than 6 months from diagnosis) and the patient has had an insufficient response to other treatments. The RAISE trial demonstrated that eltrombopag significantly increased platelet counts and reduced bleeding events compared with placebo in adult chronic ITP patients.
- Chronic Hepatitis C-Associated Thrombocytopenia: Patients with chronic hepatitis C virus (HCV) infection often develop thrombocytopenia due to liver disease, portal hypertension, and direct viral effects on megakaryocytes. This thrombocytopenia can prevent the initiation or continuation of interferon-based antiviral therapy, which requires adequate platelet counts. Eltrombopag is indicated to increase platelet counts in these patients to enable the initiation and maintenance of interferon-based therapy. The ENABLE studies showed that eltrombopag allowed a significantly higher proportion of patients to initiate and maintain antiviral therapy compared with placebo.
- Severe Aplastic Anemia (SAA): Aplastic anemia is a rare but serious bone marrow failure disorder characterized by pancytopenia – low red blood cells, white blood cells, and platelets. Eltrombopag is indicated for adult patients with SAA who have had an insufficient response to at least one course of immunosuppressive therapy (typically a combination of anti-thymocyte globulin and cyclosporine). The EMANES study demonstrated that adding eltrombopag to standard immunosuppressive therapy improved overall response rates, including trilineage blood cell recovery, suggesting that eltrombopag may stimulate residual hematopoietic stem cells in addition to promoting megakaryocyte development.
Eltrombopag treats the symptoms of these conditions by increasing platelet production, but it does not address the underlying autoimmune or bone marrow failure process. If treatment is discontinued, platelet counts are expected to return to pre-treatment levels within 1–2 weeks. In some ITP patients, platelet counts may fall below pre-treatment levels after discontinuation (rebound thrombocytopenia), increasing the risk of bleeding. Dose reduction should be gradual rather than abrupt.
What Should You Know Before Taking Eltrombopag Teva?
Contraindications
Eltrombopag Teva is contraindicated in patients with known hypersensitivity to eltrombopag or to any of the excipients listed in the formulation. While there are no absolute contraindications beyond hypersensitivity, several clinical situations require extreme caution and careful risk-benefit assessment before initiating therapy.
Patients with moderate to severe hepatic impairment (Child-Pugh score ≥7) should not be treated with eltrombopag for ITP unless the expected benefit outweighs the identified risk of portal venous thrombosis. In patients with chronic hepatitis C-associated thrombocytopenia and advanced liver disease, the risk of hepatic decompensation and thromboembolic events must be carefully weighed against the potential benefit of enabling antiviral therapy. Clinical trials have shown an increased incidence of hepatic decompensation in patients with advanced liver disease receiving eltrombopag.
Warnings and Precautions
Eltrombopag can cause serious liver injury, including elevated liver enzymes (ALT, AST) and bilirubin. Liver function tests must be performed before starting treatment, every 2 weeks during dose adjustment, and monthly once on a stable dose. If ALT levels rise to ≥3 times the upper limit of normal (ULN) and are progressive, persistent for ≥4 weeks, accompanied by increased direct bilirubin, or accompanied by clinical symptoms of liver injury, discontinue eltrombopag.
Several important warnings and precautions should be considered when using eltrombopag:
- Thromboembolic events: Excessive increases in platelet count may increase the risk of thromboembolic complications, including deep vein thrombosis (DVT), pulmonary embolism (PE), transient ischemic attack (TIA), and stroke. The risk is particularly elevated in patients with known thrombophilia, chronic liver disease, or other prothrombotic conditions. Do not use eltrombopag to normalize platelet counts; the goal is to achieve a count sufficient to reduce bleeding risk (generally ≥50 × 109/L). Platelet counts should be monitored weekly during dose adjustment and monthly once stable.
- Bone marrow reticulin formation: Thrombopoietin receptor agonists, including eltrombopag, may increase reticulin fiber deposition in the bone marrow. Reticulin is a type of collagen fiber, and its excessive accumulation can lead to bone marrow fibrosis, potentially impairing normal hematopoiesis. A peripheral blood smear should be examined before starting treatment and periodically during treatment to assess for signs of myelofibrosis, such as teardrop red blood cells, nucleated red blood cells, or immature white blood cells. If new or worsening morphological abnormalities are detected, consider bone marrow biopsy with staining for fibrosis.
- Cataracts: Cataracts have been observed in clinical studies with eltrombopag, both in preclinical animal studies and in human clinical trials. While a causal relationship has not been definitively established, regular ophthalmological examinations are recommended before and during treatment with eltrombopag, particularly for long-term use.
- Loss of response: Loss of response or failure to maintain a platelet response at a recommended dose of eltrombopag should prompt a search for causative factors, including bone marrow fibrosis. A peripheral blood smear and complete blood count should be performed, and if abnormalities are detected, eltrombopag should be discontinued and a bone marrow biopsy with reticulin staining considered.
Pregnancy and Breastfeeding
There are limited data on the use of eltrombopag in pregnant women. Animal studies have shown evidence of embryo-fetal toxicity, including reduced fetal body weight and increased pre- and post-implantation loss at doses that were also maternally toxic. Eltrombopag should not be used during pregnancy unless clearly necessary and only if the potential benefit to the mother justifies the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment.
It is not known whether eltrombopag or its metabolites are excreted in human breast milk. In animal studies, eltrombopag was detected in milk at concentrations higher than in plasma. A risk to the breastfed infant cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue eltrombopag treatment, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Special Populations
Patients of East Asian ancestry (such as Japanese, Chinese, Taiwanese, Thai, and Korean descent) may have higher eltrombopag plasma exposure due to pharmacokinetic differences. These patients should be initiated at a reduced dose of 25 mg once daily (rather than the standard 50 mg starting dose for ITP) and monitored closely for adverse effects. Dose adjustments should follow the same platelet count–based titration guidelines as for other patients.
In patients with hepatic impairment, eltrombopag clearance is reduced, resulting in higher drug exposure. For patients with ITP and mild hepatic impairment (Child-Pugh class A), no dose adjustment is generally required, but close monitoring is recommended. For moderate to severe hepatic impairment (Child-Pugh class B or C), the starting dose should be reduced to 25 mg once daily, with careful dose titration based on platelet count response and tolerability.
How Does Eltrombopag Teva Interact with Other Drugs?
Eltrombopag has several important drug interactions that healthcare providers and patients should be aware of. Unlike monoclonal antibodies, eltrombopag is a small molecule that undergoes hepatic metabolism and is subject to interactions through both chelation and enzyme/transporter inhibition mechanisms.
Major Interactions
Eltrombopag chelates with polyvalent cations (aluminum, calcium, iron, magnesium, selenium, zinc) in the gastrointestinal tract, forming insoluble complexes that dramatically reduce eltrombopag absorption. Studies show that co-administration with an aluminum/magnesium-containing antacid reduced eltrombopag AUC by approximately 70%. Always take eltrombopag at least 2 hours before or 4 hours after these products.
| Interacting Drug/Class | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Antacids (Al/Mg-containing) | Chelation | 70% reduction in eltrombopag absorption | Take 2 hours before or 4 hours after |
| Calcium supplements, dairy products | Chelation | Significant reduction in absorption | Take 2 hours before or 4 hours after |
| Iron supplements | Chelation | Significant reduction in absorption | Take 2 hours before or 4 hours after |
| Rosuvastatin | OATP1B1 and BCRP inhibition | 55% increase in rosuvastatin Cmax, 59% increase in AUC | Consider dose reduction of rosuvastatin; monitor for statin toxicity |
| Methotrexate | BCRP inhibition | Potential increase in methotrexate exposure | Monitor for methotrexate-related toxicity |
| Theophylline, caffeine | CYP1A2 inhibition | Potential increase in substrate levels | Monitor theophylline levels; be aware of caffeine sensitivity |
| Repaglinide, paclitaxel | CYP2C8 inhibition | Potential increase in substrate levels | Monitor blood glucose with repaglinide; adjust paclitaxel dose if needed |
| Ciclosporin (cyclosporine) | OATP1B1 and BCRP inhibition by ciclosporin | May reduce eltrombopag plasma levels; 25% decrease in AUC observed | Monitor platelet counts when starting or stopping ciclosporin |
Minor Interactions
Eltrombopag is primarily metabolized through UGT1A1 and UGT1A3 (glucuronidation), CYP1A2, CYP2C8, and to a lesser extent through CYP3A4 oxidation pathways. Potent inhibitors or inducers of these enzymes may alter eltrombopag plasma concentrations, though clinically significant interactions through these metabolic pathways have not been consistently demonstrated in clinical studies.
Proton pump inhibitors (PPIs) such as omeprazole and pantoprazole do not significantly affect eltrombopag pharmacokinetics and can be used concomitantly. Similarly, commonly used medications such as paracetamol (acetaminophen), NSAIDs, and most antibiotics do not have clinically relevant interactions with eltrombopag. However, patients should always inform their healthcare provider about all medications they are taking, including over-the-counter products and herbal supplements.
Lopinavir/ritonavir (used in HIV treatment) has been shown to reduce eltrombopag plasma levels by approximately 17%. While this reduction is generally not considered clinically significant, patients taking lopinavir/ritonavir should be monitored for adequate platelet count response.
What Is the Correct Dosage of Eltrombopag Teva?
Eltrombopag dosing is individualized based on the patient’s platelet count response. The goal of treatment is to achieve and maintain a platelet count sufficient to reduce the risk of bleeding, not to normalize the platelet count. Treatment should be initiated and supervised by a physician experienced in the management of hematological conditions.
Adults with Chronic ITP
Standard Dosing – Adults with ITP
Starting dose: 50 mg once daily orally
East Asian ancestry or hepatic impairment: 25 mg once daily
Dose adjustment: Adjust in increments of 25 mg every 2 weeks based on platelet count
Maximum dose: 75 mg once daily
Target platelet count: ≥50 × 109/L (do not exceed 200 × 109/L)
Platelet count monitoring is essential for safe dose titration. Check the platelet count every week during the initial dose adjustment phase, then monthly once a stable dose has been established. The following dose adjustment guidelines apply:
| Platelet Count | Action |
|---|---|
| <50 × 10⁹/L after 2 weeks | Increase dose by 25 mg (max 75 mg/day) |
| 50–200 × 10⁹/L | Maintain current dose |
| 200–400 × 10⁹/L | Decrease dose by 25 mg; reassess in 2 weeks |
| >400 × 10⁹/L | Stop eltrombopag; increase monitoring frequency. Resume at reduced dose once <150 × 10⁹/L |
Children with Chronic ITP
Pediatric Dosing – Children 1–17 Years with Chronic ITP
Ages 6–17 years: 50 mg once daily (25 mg for East Asian ancestry)
Ages 1–5 years: 25 mg once daily
Maximum dose: 75 mg once daily
Monitoring: Same platelet count–based titration as adults
Adults with Severe Aplastic Anemia
Dosing – Severe Aplastic Anemia (in combination with immunosuppressive therapy)
Starting dose: 50 mg once daily (25 mg for East Asian ancestry)
Dose adjustment: Increase by 25 mg every 2 weeks to maximum 150 mg once daily
Duration: Treatment duration is typically 6 months as part of first-line combination therapy
Missed Dose
If you miss a dose of Eltrombopag Teva, take it as soon as you remember on the same day. Do not take two doses on the same day to make up for a missed dose. Take the next dose at your regular scheduled time the following day. Missing occasional doses is unlikely to cause significant changes in platelet count, but consistent adherence to the prescribed dosing schedule is important for optimal platelet count control.
Overdose
In the event of an overdose, platelet counts may rise excessively, potentially increasing the risk of thromboembolic complications. There is no specific antidote for eltrombopag overdose. In cases of suspected overdose, monitor platelet counts closely and provide supportive care as needed. Hemodialysis is not expected to be effective in removing eltrombopag from the circulation, as the drug is highly protein-bound (>99.9%). Consider oral administration of metal cation-containing preparations such as calcium, aluminum, or magnesium supplements to chelate eltrombopag in the gastrointestinal tract and reduce further absorption.
Take Eltrombopag Teva on an empty stomach, either 1 hour before or 2 hours after a meal. Wait at least 2 hours before consuming dairy products, calcium-fortified juices, antacids, or mineral supplements. Swallow the tablet whole with water; do not crush, chew, or break the tablet. Take the tablet at approximately the same time each day to maintain consistent drug levels.
What Are the Side Effects of Eltrombopag Teva?
Like all medicines, Eltrombopag Teva can cause side effects, although not everybody gets them. The side effect profile of eltrombopag has been characterized through extensive clinical trial programs involving thousands of patients with ITP, chronic hepatitis C, and severe aplastic anemia. The frequency and type of side effects may vary depending on the indication being treated and the presence of underlying conditions.
The following side effect classification uses the standard medical frequency categories defined by the Council for International Organizations of Medical Sciences (CIOMS):
Very Common
Affects more than 1 in 10 patients
- Headache
- Nausea
- Diarrhea
- Elevated liver enzymes (ALT, AST) – particularly in hepatitis C patients
- Fatigue
Common
Affects 1 in 10 to 1 in 100 patients
- Upper respiratory tract infection (nasopharyngitis, pharyngitis)
- Urinary tract infection
- Decreased appetite
- Insomnia
- Dry mouth
- Vomiting
- Abdominal pain
- Alopecia (hair loss)
- Rash
- Pruritus (itching)
- Musculoskeletal pain (back pain, myalgia, arthralgia)
- Paresthesia (tingling or numbness)
- Cataracts
- Elevated bilirubin
- Ecchymosis (bruising)
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Thromboembolic events (deep vein thrombosis, pulmonary embolism, stroke)
- Hepatotoxicity (drug-induced liver injury)
- Reticulin deposition in bone marrow
- Renal impairment
- Skin discoloration (skin yellowing)
- Hyperbilirubinemia
- Menorrhagia (heavy menstrual bleeding)
- Peripheral neuropathy
Rare
Affects less than 1 in 1,000 patients
- Bone marrow fibrosis (myelofibrosis)
- Severe hypersensitivity reactions
- Severe hepatic injury requiring transplantation
- Thrombotic microangiopathy
- Posterior reversible encephalopathy syndrome (PRES)
Not Known
Frequency cannot be estimated from available data
- Skin discoloration (hyperpigmentation)
- Tumor lysis syndrome (in patients with hematological malignancies)
Contact your doctor or seek emergency medical care immediately if you experience: yellowing of the skin or eyes (jaundice), unusually dark urine, unusual right-sided abdominal pain, unusual tiredness (possible signs of liver problems), sudden shortness of breath or rapid breathing (possible pulmonary embolism), leg pain or swelling (possible deep vein thrombosis), sudden severe headache, visual changes, or weakness on one side of the body (possible stroke), or signs of severe allergic reaction including difficulty breathing, facial swelling, or widespread rash.
If you experience any side effects, including any not listed above, tell your doctor or pharmacist. You can also report side effects directly to your national pharmacovigilance authority. By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Eltrombopag Teva?
Proper storage of Eltrombopag Teva is important to maintain the efficacy and safety of the medication throughout its shelf life. The film-coated tablets should be stored at a temperature not exceeding 30°C (86°F). Do not refrigerate or freeze the tablets. Store the tablets in the original blister packaging to protect them from moisture and light.
Keep Eltrombopag Teva out of the sight and reach of children. Children may accidentally ingest the medication, which could be harmful. Do not use this medicine after the expiry date stated on the carton and blister after “EXP.” The expiry date refers to the last day of that month.
Do not use this medicine if you notice any visible signs of deterioration, such as discoloration, crumbling, or damage to the tablets or packaging. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment.
What Does Eltrombopag Teva Contain?
The active substance in Eltrombopag Teva is eltrombopag. Each film-coated tablet contains 25 mg of eltrombopag (as eltrombopag olamine). Eltrombopag olamine is the salt form of eltrombopag that provides optimal oral bioavailability and stability in the tablet formulation.
Active Ingredient
- Eltrombopag olamine – 25 mg eltrombopag per film-coated tablet
Inactive Ingredients (Excipients)
The other ingredients are:
- Tablet core: Mannitol (E421), microcrystalline cellulose, povidone (K30), sodium starch glycolate (Type A), magnesium stearate
- Film coating: Hypromellose, titanium dioxide (E171), macrogol/polyethylene glycol, polysorbate 80
Eltrombopag Teva 25 mg film-coated tablets are round, biconvex tablets. They are supplied in PVC/PVDC-aluminum blisters in pack sizes as determined by local regulatory authorities. Not all pack sizes may be marketed in your country.
If you are allergic to any of the listed ingredients, do not take Eltrombopag Teva. Inform your doctor or pharmacist about any known allergies before starting treatment. The tablets do not contain gluten, lactose, or tartrazine.
Frequently Asked Questions About Eltrombopag Teva
Eltrombopag Teva is a generic version of Revolade (known as Promacta in the United States). Both products contain the same active substance – eltrombopag – and have been shown to be bioequivalent, meaning they are absorbed into the body at the same rate and to the same extent. The therapeutic effects, safety profile, and dosing recommendations are identical. The primary difference may be in the inactive ingredients (excipients) used in the tablet formulation, the appearance of the tablets, and the cost. Generic medicines undergo rigorous regulatory review to ensure they meet the same quality, safety, and efficacy standards as the reference product.
Yes, but timing is critical. You must not consume dairy products (milk, cheese, yogurt, ice cream) or calcium-fortified foods and beverages for at least 2 hours before and 4 hours after taking your Eltrombopag Teva tablet. The calcium in dairy products binds to eltrombopag in the stomach, forming an insoluble complex that prevents the drug from being absorbed into the bloodstream. This chelation effect can reduce the effectiveness of your medication by up to 70%. The same applies to antacids, mineral supplements, and foods fortified with calcium, iron, or other minerals.
The duration of treatment depends on your condition and your response to the medication. For chronic ITP, treatment is typically long-term, as eltrombopag does not cure the condition but rather manages platelet counts. Many patients require ongoing treatment for years. Your doctor will periodically assess whether continued treatment is necessary by attempting dose reduction or temporary treatment interruption. For severe aplastic anemia, treatment duration is typically 6 months as part of first-line combination immunosuppressive therapy. For hepatitis C-associated thrombocytopenia, treatment continues for the duration of the antiviral therapy course.
If you stop taking eltrombopag abruptly, your platelet count will typically return to pre-treatment levels within 1 to 2 weeks. In some patients, particularly those with ITP, platelet counts may fall below the levels they were at before starting treatment (rebound thrombocytopenia), which can increase the risk of bleeding. For this reason, your doctor may recommend a gradual dose reduction rather than sudden discontinuation. During and after discontinuation, your platelet count should be monitored weekly for at least 4 weeks to detect any significant drops that might require intervention.
Eltrombopag does not directly suppress the immune system. Unlike many other treatments for ITP (such as corticosteroids, rituximab, or immunoglobulins), eltrombopag works by stimulating platelet production rather than suppressing the immune-mediated destruction of platelets. This is one of its advantages as a treatment option, particularly for patients who cannot tolerate immunosuppressive therapies or who wish to avoid their side effects. However, in severe aplastic anemia, eltrombopag is used in combination with immunosuppressive agents (anti-thymocyte globulin and cyclosporine), so the overall treatment regimen does affect immune function.
Yes, thromboembolic events (blood clots) are a recognized risk of eltrombopag treatment. The risk is related to excessive increases in platelet count and is higher in patients with pre-existing risk factors for thrombosis, such as advanced age, immobility, obesity, smoking, hormonal contraceptive use, or a personal or family history of blood clots. This is why the goal of treatment is to maintain a platelet count just high enough to prevent bleeding (typically ≥50 × 109/L), not to normalize it. Your doctor will monitor your platelet count regularly and adjust the dose to minimize this risk.
References
- European Medicines Agency (EMA). Eltrombopag – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Promacta (eltrombopag) – Prescribing Information. Novartis Pharmaceuticals. Revised 2024. Available at: www.accessdata.fda.gov
- Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393–402. doi:10.1016/S0140-6736(10)60959-2
- Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–1550. doi:10.1056/NEJMoa1613878
- Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi:10.1182/bloodadvances.2019000966
- Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. doi:10.1182/bloodadvances.2019000812
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura. Technology appraisal guidance [TA293]. 2013 (updated 2019).
- Afdhal NH, Giannini EG, Vaez-Zadeh N, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716–724. doi:10.1056/NEJMoa1110709
- Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247. doi:10.1056/NEJMoa073275
Medical Editorial Team
This article has been written and reviewed by iMedic’s medical editorial team, comprising licensed physicians with specialist training in hematology and clinical pharmacology.
Medical Content
Written by iMedic Medical Editorial Team – Specialists in Hematology
Medical Review
Reviewed by iMedic Medical Review Board according to WHO, EMA, FDA, and ASH guidelines
Evidence Level
Level 1A – Based on systematic reviews and randomized controlled trials (RAISE, ENABLE, EMANES)
Conflicts of Interest
None. iMedic receives no pharmaceutical company funding or sponsorship
Last reviewed: | Next review: